LTB4R
Leukotriene B4 receptor 1
As of the edition of 20 October 2026, LTB4R (leukotriene B4 receptor 1, UniProt Q15722) has 4 drugs tested at it and 4 companies on the list, 4 on route A and 0 on route B.
Sources: UniProt, ClinicalTrials.gov, ChEMBL, FDA Orange Book and Purple Book, Pharos.
The protein
- UniProt
- Q15722
- How well studied
- Chemical tools exist; no approved drug acts on it
- Where it sits in the cell
- At a membrane
- Solved structures
- 2
- Disease areas
- Immune system; Lungs and airways; Blood and lymph; Digestive system; Skin and connective tissue; Bones, joints and muscles; Cancer; Inherited and neonatal
- Registered trials of its drugs
- 25
Drugs at this target
| Status | Count |
|---|---|
| Went quiet | 1 |
| Stopped | 3 |
| Total | 4 |
| Drug | Status | Furthest phase | US protection |
|---|---|---|---|
| Amelubant | Stopped | Phase 2 | none listed |
| Nomacopan | Stopped | Phase 3 | none listed |
| Etalocib | Went quiet | Phase 2 | none listed |
| CP-195543 | Stopped | Phase 2 | none listed |
4 of 4 drugs, the most tested first.
Companies at this target
| Where the company stands | Companies |
|---|---|
| Route A | 4 |
| Total on the list | 4 |
| Company | Route |
|---|---|
| Pfizer | Route A |
| Boehringer Ingelheim | Route A |
| Eli Lilly | Route A |
The other 1 company at LTB4R
In the product4 companies in all; 1 is not named here, and no score is.
See the 4 companies at LTB4R, ranked, with the facts behind eachRequest access. Nothing is shown until you do.